SciELO - Scientific Electronic Library Online

vol.88 número5Estudio cycEVA: casos y controles para la estimación de la efectividad de la vacuna antigripal en España, 2008-2013Estimación de la prevalencia de hipotiroidismo según diferentes métodos: dosis diaria definida, dosis diaria prescrita y registro de pacientes en tratamiento índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Revista Española de Salud Pública

versión On-line ISSN 2173-9110versión impresa ISSN 1135-5727


PUEYO VELASCO, José Ignacio  y  REJAS GUTIERREZ, Javier. Review of patient reported outcomes in the summary of the product characteristics of medicines approved in Spain. Rev. Esp. Salud Publica [online]. 2014, vol.88, n.5, pp.613-627. ISSN 2173-9110.

Background: The term "Patient Reported Outcomes" (PRO) is defined as any result assessed directly by the patient and based on his perception of the illness and its treatment. The scope of the study is to determine and compare the use of PRO measures with other types of effectiveness endpoints in the summary of the products characteristics (SPC) of medicines with active substances approved by first time from 2000 to 2012 in Spain. Methods: A review and descriptive analysis of the effectiveness endpoints used in the clinical trials described in the SPCs studied, classifying them into the following categories: PRO, clinician-reported outcomes (CROs), and laboratory test/device measurement endpoints (ML). Chi-square and Fisher exact texts were used for comparative purposes, and odds ratio to determine the strongest of association. Results: PROs were included in 65 (19.7%) of the SPCs studied. CRO were the most frequently reported 188 (57%) cases, followed by ML:128 (38,7%). PROs were included as only effectiveness endpoint in 6 medicines. A growing trend toward statistical significance (R2=0.525; p=0.079) has been observed in reporting PROs during the period of time studied. Conclusion: The use frequency of PRO in SPCs is clearly minor compared to other efficacy endpoints considered, being the difference significantly higher in case of its use as only efficacy endpoint. The therapeutic areas where PROs were most reported were nervous system medicines, immunologic system modulator medicines, respiratory system, muscle and skeleton system.

Palabras clave : Patient outcome assessment; Drug labeling; Drug approval; Quality of life.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons